Rare diseases and orphan drugs

Annali dell'Istituto Superiore di Sanita

Volumn 47, Issue 1, 2011, Pages 83-93

  Taruscio, Domenica ^a   Capozzoli, Fiorentino ^a   Frank, Claudio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Incentives; Orphan drugs; Rare diseases; Small population

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMICS; EUROPE; EUROPEAN UNION; HUMAN; ITALY; LEGAL ASPECT; ORGANIZATION; RARE DISEASE;

ACADEMIES AND INSTITUTES; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HUMANS; ITALY; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 79953072933     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-11-01-17     Document Type: Article

References (45)

1. European Parliament and the Council. Regulation (EC) 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal 2000; L 18:1-5. 22/1.
2. European Council. Recommendation of 8 June 2009 on European action in the field of rare diseases. Official Journal C151:7-10.
3. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges (COM(2008)679 final).
4. Taruscio D, Vittozzi L, Stefanov R. National plans and strategies on rare diseases in Europe. Adv Exp Med Biol 2010;686:475-91.
5. EUCERD and EUROPLAN. Joint report on initiatives and incentives in the field of rare diseases of the European Union Committee of experts on rare diseases; 2009.
6. Van Weely S, Leufkens HGM. Background paper: orphan diseases. In: Kaplan W, Laing R (Eds). Priority medicines for Europe and the world - a public health approach to innovation. Geneva: World Health Organization; 2004. Available from: mednet3.who.int/prioritymeds/report/index.htm.
7. Service RF. Orphan drugs of the future? Science 2004;303:1798.
8. Ginsburg GS, Konstance RP, Allsbroook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005;165:2331-6. (Pubitemid 41640844)
9. WHO Expert Committee on the Selection and Use of Essential Medicines. The selection and use of essential medicines: report of the WHO Expert Committee 2002. Geneva: World Health Organization; 2003. (WHO Technical Report Series, 914). Available from: www.who.int/medicines/publications/essentialmeds- committeereports/TRS-914.pdf.
10. Ferner R E, Hughes DA. The problem of orphan drugs. BMJ 2010;341:c6456.
11. Llinares J. A regulatory overview about rare diseases. In: Posada de la Paz M, Groft SC (Eds). Rare diseases epidemiology ch. 12. vol. 686. Springer; 2010.
12. Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006;61(3):355-60. (Pubitemid 43382638)
13. Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet 2008;371:2041-4. (Pubitemid 351818196)
14. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Disc. Published online 9 November 2010, 1-9.
15. Nicholl DJ, et al. Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ 2010; 341:c6466.
16. Hawkes N, Cohen D. What makes an orphan drug? BMJ 2010;341:c6459.
17. Roos J. CP, Hyry HI, Cox TM. Orphan drug pricing may warrant a competition law investigation. BMJ 2010;341:c6471.
18. Italia. Decereto Ministeriale 18 May 2001, n. 279. Regolamento di istituzione della rete nazionale delle malattie rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie, ai sensi dell'articolo 5, comma 1, lettera b), del decreto legislativo 29 aprile 1998, n. 124. Gazzetta Ufficiale - Serie Generale n. 160, 12 luglio 2001. Suppl. Ord. n. 180/L.
19. Italia. Decreto del Presidente del Consiglio dei Ministri, 9/07/1999. Atto di indirizzo e coordinamento alle Regioni ed alle Province autonome di Trento e Bolzano in materia di accertamenti utili alla diagnosi precoce delle malformazioni e di obbligatorietà del controllo per l'individuazione ed il tempestivo trattamento dell'ipotiroidismo congenito, della fenil-chetonuria e della fibrosi cistica. Gazzetta Ufficiale n. 170, 22 luglio 1999.
20. Italia. Legge 648/96. Gazzetta Ufficiale n. 300, 23 dicembre 1996.
21. Italia. Decreto Legge 17 febbraio 1998. Disposizioni urgenti in materia di sperimentazioni cliniche in campo oncologico e altre misure in materia sanitaria. Gazzetta Ufficiale n. 39, 17 febbraio 1998.
22. Italia. Decreto Ministeriale, 08 maggio 2003. Uso terapeutico di medicinale sottoposto a sperimentazione clinica. Gazzetta Ufficiale n. 173, 28 luglio 2003.
23. Italia. Legge 8 aprile 1998, n. 94. Conversione in legge, con modificazioni, del Decreto Legge 17 febbraio 1998, n. 23, recante disposizioni urgenti in materia di sperimentazioni cliniche in campo oncologico e altre misure in materia sanitaria. Gazzetta Ufficiale n. 86, 14 aprile 1998.
24. Italia. Legge 30 marzo 1971, n. 118. Conversione in legge del DL 30 gennaio 1971, n. 5 e nuove norme in favore dei mutilati ed invalidi civili. Gazzetta Ufficiale n. 82, 2 aprile1971.
25. Italia. Decreto Legge 23 novembre 1988, n. 509. Norme per la revisione delle categorie delle minorazioni e malattie invalidanti, nonché dei benefici previsti dalla legislazione vigente per le medesime categorie, ai sensi dell'articolo 2, comma 1, della legge 26 luglio 1988, numero 291. Gazzetta Ufficiale n. 278, 26 novembre 1988.
26. Taruscio D, Vittozzi L. The Italian approach to rare diseases and the action of the Italian National Centre for Rare Diseases. JPH 2009;6(4):267-71.
27. Salvatore M, Lorenzetti S, Maranghi F, Mantovani A, Taruscio D. Molecular link(s) between hepatoblastoma pathogenesis and exposure to di-(2-ethylhexyl)phthalate: a hypothesis. Folia Med (Plovdiv) 2008;50(4):17-23.
28. Magrelli A, Azzalin G, Salvatore M, Viganotti M, Tosto F, Colombo T, Devito R, Di Masi A, Antoccia A, Lorenzetti S, Maranghi F, Mantovani A, Tanzarella C, Macino G, Taruscio D. Altered microRNA Expression Patterns in Hepatoblastoma Patients. Transl Oncol 2009;18;2(3):157-63.
29. Zuntini M, Salvatore M, Pedrini E, Parra A, Sgariglia F, Magrelli A, Taruscio D, Sangiorgi L. MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. Clin Genet 2010;78(6):507-16.
30. Cialfi S, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G, Uccelletti D, Palleschi C, Barboni L, De Bernardo C, Grammatico P, Magrelli A, Salvatore M, Taruscio D, Frati L, Gulino A, Screpanti I, Talora C. Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. Br J Dermatol 2010;162(3):518-26.
31. Kodra Y, Salerno P, Agazio E, Mirabella F, Taruscio D. Accessibility and quality of Italian health and social services: the experiences of patients with neurofibromatosis type 1 and of their relatives. Ann Ig 2007;19(5):443-50.
32. Caliandro P, Grugni G, Padua L, Kodra Y, Tonali P, Gargantini L, Ragusa L, Crinò A, Taruscio D. Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. J Paediatr Child Health 2007;43(12):826-30. (Pubitemid 350150843)
33. Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, Taruscio D. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology 2009;218(3):215-20.
34. McGovern MM, Elles R, Beretta I, Somerville MJ, Hoefler G, Keinanen M, Barton D, Carson N, Dequeker E, Brdicka R, Blazkova A, Aymé S, Schnieders B, Muller CR, Dalen V, Martinez AA, Kristoffersson U, Ozguc M, Mueller H, Boone J, Lubin IM, Sequeiros J, Taruscio D, Williamson B, Mainland L, Yoshikura H, Ronchi E. Report of an international survey of molecular genetic testing laboratories. Community Genet 2007;10(3):123-31. (Pubitemid 46944287)
35. Orlando C, Verderio P, Maatman R, Danneberg J, Ramsden S, Neumaier M, Taruscio D, Falbo V, Jansen R, Casini-Raggi C, Malentacchi F, Marubini E, Pizzamiglio S, Vernelen K, Libeer JC, Palicka V, Pazzagli M. EQUAL-qual: a European program for external quality assessment of genomic DNA extraction and PCR amplification. Clin Chem 2007;53(7):1349-57. (Pubitemid 47020993)
36. Taruscio D, Falbo V, Floridia G, Salvatore M, Pescucci C, Cantafora A, Marongiu C, Baroncini A, Calzolari E, Cao A, Castaldo G, Bricarelli FD, Guanti G, Nitsch L, Pignatti PF, Rosatelli C, Salvatore F, Zuffardi O. Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance. Clin Chem Lab Med 2004;42(8):915-21.
37. Salvatore M, Falbo V, Floridia G, Censi F, Tosto F, Bombieri C, Castaldo G, Pignatti PF, Rosatelli MC, Taruscio D. The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity. Clin Chem Lab Med 2007;45(2):254-60. (Pubitemid 46294700)
38. Falbo V, Floridia G, Tosto F, Censi F, Salvatore M, Ravani A, Ferlini A, Melis MA, Grasso M, Bricarelli FD, Taruscio D. The Italian External Quality Assessment scheme for fragile x syndrome: the results of a 5-year survey. Genet Test 2008;12(2):279-88. (Pubitemid 351860442)
39. Floridia G, Falbo V, Censi F, Tosto F, Salvatore M, Baroncini A, Battaglia P, Conti A, Donti E, La Starza R, Nitsch L, Pierluigi M, Piombo G, Susca F, Mancini M, Mecucci C, Calzolari E, Dagna Bricarelli F, Guanti G, Taruscio D. The Italian external quality assessment scheme in classical cytogenetics: four years of activity. Community Genet 2008;11(5):295-303. (Pubitemid 351725041)
40. Tosto F, Salvatore M, Falbo V, Floridia G, Censi F, Bombieri C, Rosatelli MC, Taruscio D. The Italian scheme of External Quality Assessment for beta-thalassemia: genotyping and reporting results and testing strategies in a 5-year survey. Genet Test Mol Biomarkers 2009;13(1):31-6.
41. Censi F, Falbo V, Floridia G, Salvatore M, Tosto F, De Rosa M, Resta N, Izzo P, Guanti G, Taruscio D. The Italian external quality control program for familial adenomatous polyposis of the colon: five years of experience. Genet Test Mol Biomarkers 2010;14(2):175-81.
42. Salerno P, Bianchi F, Pierini A, Baldi F, Carbone P, Mantovani A, Taruscio D. Folic acid and congenital malformation: scientific evidence and public health strategies. Ann Ig 2008;20(6):519-30.
43. European Food Safety Agency. ESCO Report on analysis of risks and benefits of fortification of food with folic acid. Parma: EFSA; 2009. Available from: www.efsa.europa.eu/en/scdocs/doc/3e.pdf.
44. European Food Safety Agency Folic acid: an update on scientific developments. Parma: EFSA; 2009. Available from: www.efsa.europa.eu/EFSA/efsa- locale-1178620753812-1211902253891.htm.
45. Knight AW, Taruscio D. International conferences on rare diseases: initiatives in commitment, patient care and connections. Med J Aust 2007;187(2):74-6. (Pubitemid 47162350)